12:00 AM
 | 
Oct 14, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Xolair omalizumab: Phase III data

The double-blind, international Phase III ASTERIA I trial in 318 patients ages 12-75 with moderate to severe CIU showed that all 3 doses of subcutaneous omalizumab given every 4 weeks for 24 weeks met the primary endpoint of reducing mean weekly ISS score from baseline to week 12 vs. placebo. Specifically, omalizumab reduced mean weekly ISS scores by 6.5 points at the 75 mg dose (p=0.001), 6.7 points at the 150 mg dose (p=0.0012) and 9.4 points at the 300 mg dose (p<0.0001) vs. 3.6 points for placebo. Novartis said the ISS benefit was maintained through week 24. High-dose omalizumab also met the...

Read the full 492 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >